A Fixed-dose Combination of Olmesartan Medoxomil (OM), Amlodipine (AML), and Hydrochlorothiazide (HCTZ): Use of Modeling and Simulation to Support an Understanding of the Dose Response of Intermediate Dose Combinations not Included in the Pivotal Phase 3 Study

Author(s): Timothy Carrothers, Michelle Green, Helen Moore, Shashank Rohatagi, SaeHeum Song, James Lee, Antonia Wang, Reinilde Heyrman, Daniel Salazar